Table II.
Differences in patient characteristics between responders and nonresponders in patients with CVID
| Characteristic | Responder (Luminex-S > 22.87 BAU/mL) (N = 154) |
Nonresponder (Luminex-S ≤ 22.87 BAU/mL) (N = 35) |
P value |
|---|---|---|---|
| Sex: male, n (%) | 62 (40.3) | 14 (40.0) | .997 |
| Age (y), mean ± SD | 46.3 ± 16.4 | 51.5 ± 10.0 | .017∗ |
| Genetic defect known, n (%) | 23 (14.9) | 6 (17.1) | .744 |
| Noninfectious complications present, n (%) | 83 (53.9) | 29 (82.9) | .002 |
| Autoimmune cytopenia | 8 (5.2) | 12 (34.3) | <.0001 |
| Other autoimmune diseases | 28 (18.2) | 11 (31.4) | .080 |
| Enteropathy | 22 (14.3) | 3 (8.6) | .580 |
| Malignancy | 9 (5.8) | 5 (14.3) | .143 |
| Lymphoproliferative diseases | 12 (7.8) | 16 (45.7) | <.0001 |
| Granulomatous-lymphocytic interstitial lung disease | 13 (8.4) | 15 (42.9) | <.0001 |
| Other granulomatous diseases | 3 (1.9) | 4 (11.4) | .023 |
| Immunosuppressive medicine(s) used in last 2 y,∗ n (%) | 37 (24.0) | 16 (45.7) | .010 |
| Immunosuppressive medicine(s) used during vaccination period, n (%) | 29 (18.8) | 13 (37.1) | .019 |
| Steroids | 16 (10.4) | 6 (17.1) | .254 |
| Anti–TNF-α | 4 (2.6) | 3 (8.6) | .120 |
| Azathioprine | 3 (1.9) | 3 (8.6) | .078 |
| Rituximab (year of treatment) | 2 (1.3) (2017) | 2 (5.7) (2014, 2017, 2020) | .157 |
∗
Independent t test. All other P values are calculated using Pearson χ2 test, except for parameters with total (expected) cell counts <5 (Fischer exact test).